# Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

> **NCT05146999** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 132 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** QM1114-DP
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05146999
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-10-28
- **Final completion:** 2023-09-01
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146999, "Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05146999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*